A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Eli Lilly just gave investors several reasons to cheer.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback